1. Satterwhite, CL, Torrone, E, Meites, E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.
Google Scholar | Crossref2. Arbyn, M, Castellsagué, X, de Sanjosé, S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.
Google Scholar | Crossref | Medline3. Lowy, DR, Schiller, JT. Reducing HPV-associated cancer globally. Cancer Prev Res. 2012;5(1):18–23.
Google Scholar | Crossref4. Meites, E, Szilagyi, PG, Chesson, HW, Unger, ER, Romero, JR, Markowitz, LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698–702.
Google Scholar | Crossref | Medline5. Walker, TY, Elam-Evans, LD, Singleton, JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(33):874.
Google Scholar | Crossref | Medline6. Velentzis, LS, Sitas, F, O’Connell, DL, et al. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study. BMC Infect Dis. 2014;14(1):3861.
Google Scholar | Crossref | Medline7. Harper, DM, DeMars, LR. HPV vaccines: a review of the first decade. Gynecol Oncol. 2017;146(1):196–204.
Google Scholar | Crossref | Medline8. Australian Government Department of Health . The Australian Immunisation Handbook. Department of Health and Ageing; 2013. Canberra.
Google Scholar9. Schwarz, TF, Spaczynski, M, Schneider, A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009;27(4):581–7.
Google Scholar | Crossref10. Westra, TA, Rozenbaum, MH, Rogoza, RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011;204(3):377–84.
Google Scholar | Crossref | Medline11. Mazza, D, Petrovic, K, Grech, C, Harris, N. HPV vaccination in women aged 27 to 45 years: what do general practitioners think? BMC Womens Health. 2014;14(1):91.
Google Scholar | Crossref | Medline12. U.S. Food and Drug Administration . FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 through 45 Years Old. 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old
Google Scholar13. Sanders, GD, Taira, AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37–48.
Google Scholar | Crossref | Medline14. Elbasha, EH, Dasbach, EJ, Insinga, RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28.
Google Scholar | Crossref | Medline | ISI15. Chesson, HW, Ekwueme, DU, Saraiya, M, Markowitz, LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244–51.
Google Scholar | Crossref | Medline16. Chesson, HW, Ekwueme, DU, Saraiya, M, Dunne, EF, Markowitz, LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443–50.
Google Scholar | Crossref17. Guzzetta, G, Faustini, L, Panatto, D, Gasparini, R, Manfredi, P. The impact of HPV female immunization in Italy: model based predictions. PLoS One. 2014;9(3):e91698.
Google Scholar | Crossref | Medline | ISI18. Brisson, M, Laprise, J. Cost-effectiveness of extending HPV vaccination above age 26 years in the U.S. 2019. Available from: https://stacks.cdc.gov/view/cdc/78081/cdc_78081_DS1.pdf
Google Scholar19. Van de Velde, N, Brisson, M, Boily, MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine. 2010;28(33):5473–84.
Google Scholar | Crossref | Medline20. Winer, RL, Lee, SK, Hughes, JP, Adam, DE, Kiviat, NB, Koutsky, LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–26.
Google Scholar | Crossref | Medline21. Dempsey, AF . Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol. 2008;1(3):122.
Google Scholar | Medline22. Shi, R, Devarakonda, S, Liu, L, Taylor, H, Mills, G. Factors associated with genital human papillomavirus infection among adult females in the United States, NHANES 2007–2010. BMC Res Notes. 2014;7(1):544.
Google Scholar | Crossref | Medline23. Romanowski, B, Schwarz, TF, Ferguson, L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccines Immunother. 2016;12(1):20–9.
Google Scholar | Crossref | Medline24. Wheeler, CM, Skinner, SR, Del Rosario-Raymundo, MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–68.
Google Scholar | Crossref | Medline25. Matthijsse, SM, van Rosmalen, J, Hontelez, JA, et al. The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model. PLoS One. 2015;10(2):e0116618.
Google Scholar | Crossref | Medline26. Chaturvedi, AK . Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(4):S20–6.
Google Scholar | Crossref | Medline27. Schiffman, MH, Bauer, HM, Hoover, RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85(12):958–64.
Google Scholar | Crossref | Medline28. Tong, SY, Lee, YS, Park, JS, Bae, SN, Lee, JM, Namkoong, SE. Clinical analysis of synchronous primary neoplasms of the female reproductive tract. Eur J Obstet Gynecol Reprod Biol. 2008;136(1):78–82.
Google Scholar | Crossref | Medline29. Moscicki, A-B, Palefsky, J, Gonzales, J, Schoolnik, GK. Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors. Pediatr Res. 1990;28(5):507–13.
Google Scholar | Crossref | Medline30. Reiter, PL, McRee, AL. HPV infection among sexual minority women: does it matter how sexual orientation is measured? Cancer Epidemiol Prevent Biomarkers. 2016;25(3):559–60.
Google Scholar | Crossref31. Chen, T, Guestrin, C. 2016. Xgboost: a scalable tree boosting system. In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, edited by Krishnapuram, Balaji , 785–94. San Francisco: Association for Computing Machinery.
Google Scholar | Crossref32. Nielsen, D . Tree boosting with XGBoost: why does XGBoost win “every” machine learning competition? Master’s thesis, NTNU, 2016.
Google Scholar33. Howlader, N, Noone, AM, Krapcho, M, et al. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013.
Google Scholar34. Arias, E, Heron, M, Xu, J. United States life tables , 2012. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics Report. 2016;65(8):1.
Google Scholar35. Aschengrau, A, Seage, GR. Essentials of Epidemiology in Public Health. Burlington, MA: Jones & Bartlett; 2013.
Google Scholar36. Beck, JR, Pauker, SG, Gottlieb, JE, Klein, K, Kassirer, JP. A convenient approximation of life expectancy (the “DEALE”): II. Use in medical decision-making. Am J Med. 1982;73(6):889–97.
Google Scholar | Crossref37. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) . National Health and Nutrition Examination Survey Data 2011–2012. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2016. Available from: https://www.cdc.gov/nchs/nhanes/nhanes2011-2012/overview_g.htm.
Google Scholar38. Ley-Chavez, A . Quantitative models to design and evaluate risk-specific screening strategies for cervical cancer prevention. Doctoral dissertation, The Ohio State University, 2012.
Google Scholar39. U.S. Census Bureau: Survey of income and program participation . Washington, DC: U.S. Department of Commerce; 2014 Available from: https://www.census.gov/programs-surveys/sipp/data/datasets.html
Google Scholar40. Molander, RC, Yonker, JA, Krahn, DD. Age-related changes in drinking patterns from mid-to older age: results from the Wisconsin longitudinal study. Alcoholism. 2010;34(7):1182–92.
Google Scholar41. Centers for Disease Control and Prevention . Quitting smoking among adults—United States, 2001–2010. MMWR Morb Mortal Wkly Rep. 2011;60:1513–9.
Google Scholar42. Dunne, EF, Markowitz, LE, Saraiya, M, et al. CDC grand rounds: reducing the burden of HPV-associated cancer and disease. MMWR Morb Mortal Wkly Rep. 2014;63(4):69–72.
Google Scholar | Medline43. Saraiya, M, Unger, ER, Thompson, TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
Google Scholar | Crossref | Medline